CJC-1295/Ipamorelin: The #1 Peptide for Women Over 40
Growth hormone output drops ~14% per decade after 30. By perimenopause, the decline is significant — driving poor sleep, body composition changes, thinning skin, and brain fog. CJC-1295/Ipamorelin restores what time takes away.
If you ask a functional medicine practitioner which peptide they prescribe most often to women over 40, the answer is almost always the same: CJC-1295/Ipamorelin. It's the workhorse combination — the peptide protocol that addresses the broadest range of perimenopause and menopause complaints through a single mechanism: restoring the body's natural growth hormone pulsing.
Growth hormone (GH) output declines approximately 14% per decade after age 30. By the time a woman reaches perimenopause, she's producing a fraction of the GH she had in her twenties. This decline contributes to poor sleep architecture (GH is released primarily during deep sleep), increased visceral fat, decreased lean muscle, thinning skin, slower recovery, and the cognitive fog that so many women describe as feeling like their brain "doesn't work anymore."
CJC-1295/Ipamorelin doesn't inject growth hormone — it restores your body's own production of it. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends the duration of GH release. Ipamorelin is a growth hormone secretagogue that triggers the pituitary to release GH in natural pulses. Together, they produce a physiological GH response — mimicking what your body used to do on its own.
Why Women Over 40 Respond So Well
The GH decline and the estrogen decline of perimenopause compound each other. Estrogen supports GH release from the pituitary — when estrogen fluctuates and drops, GH output drops further. Women in perimenopause experience a double endocrine decline that makes the effects more pronounced than the gradual GH reduction alone would cause.
CJC-1295/Ipamorelin addresses the GH side of this equation. HRT addresses the estrogen side. Together, they restore both hormonal axes that are simultaneously declining — which is why many functional medicine practitioners prescribe them in combination.
What It Does
Sleep
Growth hormone release is tightly linked to deep sleep — the majority of daily GH secretion occurs during slow-wave sleep. When GH pulsing declines, sleep quality degrades. When sleep quality degrades, GH pulsing declines further. CJC-1295/Ipamorelin taken at bedtime breaks this negative cycle by restoring the nighttime GH pulse that supports deep sleep architecture.
Body Composition
GH promotes lipolysis (fat breakdown) and lean muscle preservation. The body composition changes of perimenopause — increased visceral fat, decreased muscle mass, slower metabolism — track closely with GH decline. Restoring physiological GH levels supports healthier body composition without the risks of exogenous growth hormone injection.
Skin & Hair
GH stimulates collagen production and supports skin thickness and elasticity. The "glow" many women report after starting CJC-1295/Ipamorelin is partly explained by increased dermal collagen synthesis and improved skin hydration.
Cognition
GH receptors are present throughout the brain, and GH supports neuroplasticity, neurotransmitter synthesis, and cerebral blood flow. Restoring GH pulsing often produces noticeable improvements in mental clarity, focus, and the ability to recall words — the cognitive symptoms that many perimenopausal women find most distressing.
Why the Combination Works Better Than Either Alone
CJC-1295 alone: Extends GH release duration but doesn't initiate the pulse. Less precise timing.
Ipamorelin alone: Triggers clean GH pulse without cortisol or prolactin elevation, but shorter duration.
Combined: Ipamorelin initiates a clean GH pulse; CJC-1295 extends its duration. The result is a larger, longer, more physiological GH release — closer to what your 25-year-old pituitary produced naturally.
Monitoring & Safety
CJC-1295/Ipamorelin requires physician supervision with appropriate bloodwork monitoring. Key markers include IGF-1 (should stay within the upper-normal range, not supraphysiological), fasting glucose and HbA1c (GH can affect insulin sensitivity), and a comprehensive metabolic panel. Most practitioners check these at baseline, 6 weeks, and quarterly thereafter.
Side effects are generally mild: head rush or flushing shortly after injection (common, transient), vivid dreams (common, often considered a positive sign of restored GH pulsing), tingling or warmth in extremities, and increased appetite. Serious adverse effects are rare at physiological dosing.